EXAS logo

Exact Sciences (EXAS)

Profile

Full Name

Exact Sciences Corporation

Ticker Symbol

EXAS

Exchange

NASDAQ

Sector

Healthcare

Industry

Diagnostics & Research

Country

United States

IPO

February 1, 2001

Indexes

Not included

Website

http://www.exactsciences.com

Employees

6900

Key Details

Price

$44.76(+0.69%)

Market cap

$8.31B(Mid cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$2.76B(+10.37% YoY)

Annual EPS

-$5.59(-394.69% YoY)

PE ratio

-

Next earnings date

May 1, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$44.76
EXAS price is $44.76

30-Day Relative Volume

1.12
EXAS 30-day relative volume is 1.12

Price Performance

Price Today change

+0.69%
EXAS price is up +0.69% today

Price YTD change

-20.35%
EXAS price is down -20.35% since January 1st

Price 1-year change

-37.27%
EXAS price is down -37.27% year-on-year

Price 3-year change

-35.71%
EXAS price is down -35.71% over the past 3 years

Price Range

Price All-time high

$159.54
EXAS price is currently -71.95% below its historical high of $159.54

Price 3-year low

$29.27
EXAS price is currently +52.90% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$8.31B
EXAS market capitalization is $8.31 billion

Market cap 3-year change

-32.12%
EXAS market capitalization is down -32.12% over the past 3 years

Market cap All-time high

$26.21B
EXAS market capitalization is currently -68.28% below its historical high of $26.21 billion

Market cap sector rank

91.78%
EXAS market capitalization is higher than 91.78% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

+1.04%
EXAS shares outstanding is up +1.04% year-on-year

Shares Outstanding 3-Year Change

+5.81%
EXAS shares outstanding is up +5.81% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.78
EXAS beta is 0.78

200-day SMA

$55.78
EXAS price is currently -19.77% below its 200-day simple moving average

50-day SMA

$47.57
EXAS price is currently -5.91% below its 50-day simple moving average

RSI

48.05
EXAS 14-day relative strength index is 48.05

Volume

1.12
EXAS 30-day relative volume is 1.12

ATR

$2.75
EXAS average true range is $2.75

10-day Historical Volatility

88.40%
EXAS 10-day historical volatility is 88.40%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$2.76B
EXAS annual revenue is $2.76 billion

Revenue Analysts estimate

$3.05B
EXAS annual revenue is currently -9.69% lower than the consensus analysts' forecast

Revenue 1-year change

+10.37%
EXAS annual revenue is up +10.37% year-on-year

Revenue Sector rank

87.57%
EXAS annual revenue is higher than 87.57% of companies in Healthcare sector

EPS

EPS

-$5.59
EXAS annual earnings per share is -$5.59

EPS Analysts estimate

$0.33
EXAS annual earnings per share is currently -1773.65% lower than the consensus analysts' forecast

EPS 1-year change

-394.69%
EXAS annual earnings per share is down -394.69% year-on-year

EPS Sector rank

17.51%
EXAS annual earnings per share is higher than 17.51% of companies in Healthcare sector

Profit

Gross profit

$1.92B
EXAS annual gross profit is $1.92 billion

Gross margin

69.55%
EXAS annual gross profit margin is 69.55%

Operating profit

-$179.14M
EXAS annual operating income is -$179.14 million

Operating margin

-6.49%
EXAS annual operating profit margin is -6.49%

Net income

-$1.03B
EXAS annual net profit is -$1.03 billion

Net margin

-37.29%
EXAS annual net profit margin is -37.29%

Expenses

Total expenses

$2.94B
EXAS annual total expenses is $2.94 billion

Operating expenses

$2.10B
EXAS annual total operating expenses is $2.10 billion

Cost of goods sold

$840.20M
EXAS annual cost of goods sold is $840.20 million

Selling, general & administrative expenses

$1.67B
EXAS annual SGA is $1.67 billion

Depreciation and amortization

$214.86M
EXAS annual depreciation & amortization is $214.86 million

Interest expense

$31.97M
EXAS annual interest expense is $31.97 million

Income tax

-$7.30M
EXAS annual income tax is -$7.30 million

EBIT & EBITDA

EBIT

-$1.00B
EXAS annual earnings before interest & taxes is -$1.00 billion

EBITDA

-$789.33M
EXAS annual EBITDA is -$789.33 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$5.93B
EXAS annual total assets is $5.93 billion

Non current assets

$4.36B
EXAS annual long term assets is $4.36 billion

Current assets

$1.57B
EXAS annual total current assets is $1.57 billion

Cash and cash equivalents

$600.89M
EXAS annual cash & cash equivalents is $600.89 million

Accounts receivable

$248.97M
EXAS annual accounts receivable is $248.97 million

Inventory

$162.38M
EXAS annual inventory is $162.38 million

Liabilities

Total liabilities

$3.53B
EXAS annual total liabilities is $3.53 billion

Long term liabilities

$2.79B
EXAS annual total long term liabilities is $2.79 billion

Current liabilities

$732.19M
EXAS annual total current liabilities is $732.19 million

Accounts payable

$89.57M
EXAS annual accounts payable is $89.57 million

Debt

Total debt

$2.75B
EXAS annual total debt is $2.75 billion

Total debt 1-year change

+7.83%
EXAS annual total debt is up +7.83% year-on-year

Long term debt

$2.48B
EXAS annual long term debt is $2.48 billion

Short term debt

$276.56M
EXAS annual short term debt is $276.56 million

Equity & Capital

Shareholders equity

$2.40B
EXAS annual stockholders equity is $2.40 billion

Book value

$2.40B
EXAS annual book value is $2.40 billion

Retained earnings

-$4.50B
EXAS annual retained earnings is -$4.50 billion

Working capital

$839.24M
EXAS annual working capital is $839.24 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$210.54M
EXAS annual cash flow from operations is $210.54 million

Cash from operations 1-year change

+34.86%
EXAS annual cash flow from operations is up +34.86% year-on-year

Cash from investing

-$442.15M
EXAS annual cash flow from investing activities is -$442.15 million

Cash from investing 1-year change

-990.02%
EXAS annual cash flow from investing activities is down -990.02% year-on-year

Cash from financing

$231.87M
EXAS annual cash flow from financing activities is $231.87 million

Cash from financing 1-year change

+45.13%
EXAS annual cash flow from financing activities is up +45.13% year-on-year

CAPEX

CAPEX

$135.99M
EXAS annual capital expenditures is $135.99 million

CAPEX 1-year change

+9.5%
EXAS annual capital expenditures is up +9.5% year-on-year

Free Cash Flow

Free cash flow

$74.55M
EXAS annual free cash flow is $74.55 million

Free cash flow 1-year change

+133.48%
EXAS annual free cash flow is up +133.48% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

69.55%
EXAS annual gross profit margin is 69.55%

Operating margin

-6.49%
EXAS annual operating profit margin is -6.49%

Net margin

-37.29%
EXAS annual net profit margin is -37.29%

ROA & ROE

ROA

-16.60%
EXAS annual return on assets is -16.60%

ROE

-37.09%
EXAS annual return on equity is -37.09%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

-
EXAS price to earnings ratio value is unknown

PE ratio Sector rank

-
EXAS price to earnings ratio is unknown

PB Ratio

PB ratio

3.46
EXAS price to book ratio is 3.46

PB ratio Sector rank

75.58%
EXAS price to book ratio is higher than 75.58% of companies in Healthcare sector

PS Ratio

PS ratio

3.01
EXAS price to sales ratio is 3.01

PS ratio Sector rank

51.92%
EXAS price to sales ratio is higher than 51.92% of companies in Healthcare sector

Enterprise value

Enterprise value

$10.47B
EXAS enterprise value is $10.47 billion

Enterprise value Sector rank

92.4%
EXAS enterprise value is higher than 92.4% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

-13.07
EXAS EV/EBITDA is -13.07

EV/EBITDA Sector rank

8.95%
EXAS EV/EBITDA is higher than 8.95% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

2.15
EXAS annual current ratio is 2.15

Quick ratio

1.92
EXAS annual quick ratio is 1.92

Leverage

Debt to equity

1.07
EXAS annual debt to equity ratio is 1.07

Interest coverage ratio

-31.41
EXAS annual interest coverage ratio is -31.41

Risk & Stability

Piotroski F-Score

3
EXAS piotroski f-score is 3

Altman Z-Score

0.43
EXAS altman z-score is 0.43

Analyst ratings

Recent major analysts updates

Apr 11, 25 Guggenheim
Buy
Apr 10, 25 Mizuho
Outperform
Apr 10, 25 Barclays
Overweight
Mar 13, 25 RBC Capital
Sector Perform
Feb 26, 25 Piper Sandler
Overweight
Feb 24, 25 Scotiabank
Sector Outperform
Feb 20, 25 Barclays
Overweight
Feb 20, 25 B of A Securities
Buy
Jan 23, 25 Barclays
Overweight
Jan 13, 25 Benchmark
Buy

Institutional Ownership

Similar stocks

MASI logo
Masimo (MASI)
TECH logo
Bio-Techne (TECH)
HSIC logo
Henry Schein (HSIC)
CHE logo
Chemed (CHE)
VTRS logo
Viatris (VTRS)
NBIX logo
Neurocrine Biosciences (NBIX)
MEDP logo
Medpace Holdings (MEDP)
QGEN logo
Qiagen NV (QGEN)
ASND logo
Ascendis Pharma A/S (ASND)
  • What is the ticker symbol for Exact Sciences?
  • Does Exact Sciences pay dividends?
  • What sector is Exact Sciences in?
  • What industry is Exact Sciences in?
  • What country is Exact Sciences based in?
  • When did Exact Sciences go public?
  • Is Exact Sciences in the S&P 500?
  • Is Exact Sciences in the NASDAQ 100?
  • Is Exact Sciences in the Dow Jones?
  • When was Exact Sciences's last earnings report?
  • When does Exact Sciences report earnings?
  • Should I buy Exact Sciences stock now?

What is the ticker symbol for Exact Sciences?

The ticker symbol for Exact Sciences is NASDAQ:EXAS

Does Exact Sciences pay dividends?

No, Exact Sciences does not pay dividends

What sector is Exact Sciences in?

Exact Sciences is in the Healthcare sector

What industry is Exact Sciences in?

Exact Sciences is in the Diagnostics & Research industry

What country is Exact Sciences based in?

Exact Sciences is headquartered in United States

When did Exact Sciences go public?

Exact Sciences's initial public offering (IPO) was on February 1, 2001

Is Exact Sciences in the S&P 500?

No, Exact Sciences is not included in the S&P 500 index

Is Exact Sciences in the NASDAQ 100?

No, Exact Sciences is not included in the NASDAQ 100 index

Is Exact Sciences in the Dow Jones?

No, Exact Sciences is not included in the Dow Jones index

When was Exact Sciences's last earnings report?

Exact Sciences's most recent earnings report was on Feb 19, 2025

When does Exact Sciences report earnings?

The next expected earnings date for Exact Sciences is May 1, 2025

Should I buy Exact Sciences stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page